Oruka Therapeutics, Inc. (ORKA) key performance indicators and operating metrics (5 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Investigator’s Global Assessment 0/1 at Week 16 | 84.00 percent | FY2026-Q2 |
| Psoriasis Area and Severity Index 100 at Week 16 | 63.50 percent | FY2026-Q2 |
| Psoriasis Area and Severity Index 90 at Week 16 | 83.00 percent | FY2026-Q2 |
| Pre-funded warrant exercise price | 0.00 USD_per_share | FY2025-Q3 |
| Pre-funded warrants | 1.07M | FY2025-Q3 |
Back to ORKA overview · ORKA earnings · ORKA holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.